Jazz Pharmaceuticals PLC
JAZZ165.500USD
+2.350+1.44%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
10.05B시가총액
손실P/E TTM
자세한 내용은 Jazz Pharmaceuticals PLC 회사
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Jazz Pharmaceuticals PLC 정보
종목 코드 JAZZ
회사 이름Jazz Pharmaceuticals PLC
상장일Jan 18, 2012
CEOGala (Renee D)
직원 수2800
유형Ordinary Share
회계 연도 종료Jan 18
주소Fifth Floor, Waterloo Exchange
도시DUBLIN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Ireland
우편 번호- -
전화35316347800
웹사이트https://www.jazzpharma.com/
종목 코드 JAZZ
상장일Jan 18, 2012
CEOGala (Renee D)
Jazz Pharmaceuticals PLC의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+3507.00%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
310.79K
+18464.00%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
55.49K
+7370.00%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
31.68K
+7559.00%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
27.20K
+5577.00%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
15.00K
--
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Director
Independent Director
13.92K
+1702.00%
Ms. Anne O'Riordan
Ms. Anne O'Riordan
Independent Director
Independent Director
12.77K
+1702.00%
Ms. Samantha Pearce
Ms. Samantha Pearce
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
11.28K
+2038.00%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
7.11K
+1702.00%
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+3507.00%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
310.79K
+18464.00%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
55.49K
+7370.00%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
31.68K
+7559.00%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
27.20K
+5577.00%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
15.00K
--
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
Xywav
431.41M
38.31%
Epidiolex/epidyolex
302.61M
26.87%
Rylaze
99.87M
8.87%
Zepzelca
79.30M
7.04%
High-sodium oxybate AG royalty revenue
52.95M
4.70%
기타
159.98M
14.21%
지역별USD
이름
수익
비율
United States
1.02B
90.62%
Europe
86.41M
7.67%
All Others
19.23M
1.71%
사업별
지역별
사업별USD
이름
수익
비율
Xywav
431.41M
38.31%
Epidiolex/epidyolex
302.61M
26.87%
Rylaze
99.87M
8.87%
Zepzelca
79.30M
7.04%
High-sodium oxybate AG royalty revenue
52.95M
4.70%
기타
159.98M
14.21%
주식 보유 통계
마지막 업데이트: Thu, Dec 4
마지막 업데이트: Thu, Dec 4
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
9.70%
BlackRock Institutional Trust Company, N.A.
8.25%
Dimensional Fund Advisors, L.P.
4.67%
Capital World Investors
4.20%
LSV Asset Management
4.04%
기타
69.14%
주주
주주
비율
The Vanguard Group, Inc.
9.70%
BlackRock Institutional Trust Company, N.A.
8.25%
Dimensional Fund Advisors, L.P.
4.67%
Capital World Investors
4.20%
LSV Asset Management
4.04%
기타
69.14%
주주 유형
주주
비율
Investment Advisor
50.55%
Investment Advisor/Hedge Fund
34.46%
Hedge Fund
10.57%
Research Firm
3.49%
Individual Investor
3.09%
Pension Fund
1.75%
Venture Capital
1.30%
Bank and Trust
1.13%
Family Office
0.10%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
1196
62.93M
103.56%
-8.99M
2025Q3
1197
64.03M
105.38%
-5.21M
2025Q2
1199
63.76M
105.11%
-6.47M
2025Q1
1235
63.66M
105.15%
-6.35M
2024Q4
1202
62.66M
103.17%
-6.51M
2024Q3
1172
61.48M
99.60%
-6.16M
2024Q2
1167
61.28M
97.21%
-6.97M
2024Q1
1163
63.08M
101.15%
-2.43M
2023Q4
1156
61.76M
98.11%
-3.48M
2023Q3
1158
61.08M
96.76%
-4.05M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
5.88M
9.68%
-184.81K
-3.05%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
5.01M
8.25%
-208.46K
-3.99%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
2.84M
4.67%
+298.81K
+11.77%
Sep 30, 2025
Capital World Investors
2.55M
4.2%
+10.35K
+0.41%
Sep 30, 2025
LSV Asset Management
2.51M
4.13%
-41.88K
-1.64%
Sep 30, 2025
State Street Investment Management (US)
1.87M
3.07%
-67.50K
-3.49%
Sep 30, 2025
EcoR1 Capital, LLC
1.71M
2.81%
--
--
Sep 30, 2025
JP Morgan Asset Management
1.70M
2.8%
+152.32K
+9.83%
Sep 30, 2025
Fuller & Thaler Asset Management Inc.
1.63M
2.68%
-2.82K
-0.17%
Sep 30, 2025
Columbia Threadneedle Investments (US)
1.57M
2.58%
+29.17K
+1.89%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Cambria Cannabis ETF
4.08%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
3.11%
iShares U.S. Pharmaceuticals ETF
3.08%
Invesco Pharmaceuticals ETF
2.94%
State Street SPDR S&P Pharmaceuticals ETF
2.83%
Abacus FCF International Leaders ETF
2.69%
First Trust NASDAQ Pharmaceuticals ETF
2.51%
Clough Hedged Equity ETF
2.4%
Alger Russell Innovation ETF
2.12%
VictoryShares Small Cap Free Cash Flow ETF
1.77%
더 보기
Cambria Cannabis ETF
비율4.08%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
비율3.11%
iShares U.S. Pharmaceuticals ETF
비율3.08%
Invesco Pharmaceuticals ETF
비율2.94%
State Street SPDR S&P Pharmaceuticals ETF
비율2.83%
Abacus FCF International Leaders ETF
비율2.69%
First Trust NASDAQ Pharmaceuticals ETF
비율2.51%
Clough Hedged Equity ETF
비율2.4%
Alger Russell Innovation ETF
비율2.12%
VictoryShares Small Cap Free Cash Flow ETF
비율1.77%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
